Skip to content

Analysis of Hyperthermia as an Adjunctive Treatment to Evidence-based Clinical Intervention in Subjects With Plantar Fasciitis: a Double-blind Randomized Clinical Trial

Analysis of Hyperthermia as an Adjunctive Treatment to Evidence-based Clinical Intervention in Subjects With Plantar Fasciitis: a Double-blind Randomized Clinical Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07103226
Enrollment
64
Registered
2025-08-05
Start date
2025-08-01
Completion date
2027-03-31
Last updated
2025-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperthermia, Plantar Fascia

Brief summary

This project aims to analyze the use of hyperthermia within a treatment protocol for plantar fasciitis, as well as to determine the difference between two and three sessions per week. Study participants will be divided into four intervention groups: the first will receive two sessions per week for a period of six months, while the second will receive three sessions per week for the same period. The treatment protocol will consist of therapeutic physical exercise focused on the foot muscles and stretching the plantar fascia and posterior chain, hyperthermia on the plantar fascia insertion area in the calcaneus and adjacent areas, and the use of an orthotic insole used for walking. The third and fourth intervention groups will receive the same treatment as mentioned above, but without hyperthermia. The third group will receive three sessions per week, while the second group will receive two sessions per week. Two different types of measurement variables will be used: objective variables will be used to measure local pain using an algometer, assess ankle joint range of motion, and use ultrasound imaging techniques. Subjective variables will also be used through validated questionnaires, which will address physical activity, perceived functional limitations in patients with lower limb pathologies, lower limb functional assessment, and a visual analogue scale for pain perception.

Interventions

RADIATIONHyperthermia

Hyperthermia will be applied for a period of 15 to 20 minutes in the area to be treated, maintaining a thermal sensation of gentle heat for the patient and accompanied by active-assisted or passive mobilization of the structures adjacent to the plantar fascia.

OTHERPhysical Exercise

The therapeutic physical exercise focused on the flexor muscles of the foot will consist of 3 periods of isometric contraction of 15 seconds, with a rest period of 30 seconds, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.

OTHERStretching

The plantar fascia stretch will be performed with the patient in the supine position. Maximum dorsiflexion will be achieved, and the lower limb will be elevated with the knee extended as tolerated. This procedure will be performed three times in a row for 30 seconds, with a 1-minute rest between each stretch.

Imposition of an orthopedic insole

Sponsors

University of Malaga
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Have a diagnosis confirmed by performing an ultrasonography of Plantar Fascitis * Have not yet received physiotherapy treatment.

Exclusion criteria

* Have undergone surgery. * Those who refuse to participate in this study. * Patients with muscle atrophy due to plantar fasciitis. * Medical conditions that are contraindications for hyperthermia therapy.

Design outcomes

Primary

MeasureTime frameDescription
FOOT AND ANKLE ABILITY MEASURE (FAAM)Baseline and up to one yearThis instrument is based on the subjective assessment of physical function and activities of daily living in patients with musculoskeletal disorders of the lower limb. It consists of 29 items, divided into two subscales: activities of daily living (21 items) and sports activities (8 items). Each question can be scored on a scale from 4 (no difficulty) to 0 (total inability to perform the activity in question). The maximum score is 84 for the activities of daily living subscale and 32 for sports activities, representing full functionality. The Spanish version has been shown to be correctly translated from its original version and to present a correct structure, internal consistency, reliability, correlation between the total items and between items, and validity.
LOWER EXTREMITY FUNCTIONAL SCALE (LEFS)Baseline and up to one yearThis questionnaire assesses perceived functionality in patients with a musculoskeletal problem in the lower limb. It consists of 20 questions, each of which is scored by the patient, ranging from 0 (extreme difficulty or inability to perform the activity) to 4 (no difficulty). The maximum score is 80 (no functional limitations), and the minimum score of 0 indicates extreme limitation. The Spanish adaptation has demonstrated similar values to the English version in the areas of internal consistency, reliability, structure, and error.
International Physical Activity Questionnaire (IPAQ)Baseline and up to one yearThis instrument is designed to measure physical activity levels in an adult population and can serve as a reference for making recommendations regarding physical activity. It comes in two versions: the long version with 31 items (IPAQ-LF) and the short version with 9 items (IPAQ-SF). The short version, which will be used in this study as recommended by the authors, measures activity at four intensity levels, ranging from 1 (vigorous-intensity activity) to 4 (sedentary). It has very good reliability (r=0.8).
Visual Analogue Scale (VAS)Baseline and up to one yearIt consists of an 11-point numerical scale, ranging from 0 (no pain) to 10 (maximum pain intensity), which serves as a quantification for measuring pain intensity. It has moderate to good reliability.
PRESSURE PAIN THRESHOLD (PPT)Baseline and up to one yearPressure Pain Threshold (PPT) has proven to be a reliable method for measuring pain intensity in patients with plantar fasciitis. To perform this test, the patient is placed prone, and the most painful point under the heel is palpated. Once located, a portable mechanical pressure algometer is used, increasing pressure at a rate of 30 kPa/s. The patient is provided with a portable switch that they can activate when the session changes from pressure to pain. This procedure is repeated three times, with a 30-second rest period between tests.
WEIGHT-BEARING LUNGE TEST (WBLT)Baseline and up to one yearThe Weight-Bearing Lunge Test (WBLT) is a reliable method for measuring ankle joint range of motion by measuring the maximum anterior displacement of the tibia on the talus in a weight-bearing position. The patient stands facing a wall with their fingers on the wall for balance and the healthy limb 30 centimeters behind the affected limb. The affected foot is placed parallel to a tape measure with the knee perpendicular to the wall, with the foot remaining in full contact with the floor. The patient is asked to touch the wall with their knee, without lifting their heel from the floor, doing this four times: the first attempt is to measure the distance from the wall, and the remaining three are used as measurements, with the average being recorded.
UltrasonographyBaseline and up to one yearUltrasound imaging is an excellent noninvasive method for analyzing foot structures, including the plantar fascia. To do this, the patient is placed prone, and the transducer is positioned on the plantar surface of the heel, pointing toward the second toe, to assess the insertion of the plantar fascia into the medial tuberosity of the calcaneus. Subsequently, using the ultrasound software, three successive measurements of plantar fascia thickness are taken, first on the symptomatic foot and then on the contralateral foot. This measurement has proven to be a reliable method for assessing the plantar fascia.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026